

# Birte Yding Glenthj

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8644273/birte-yding-glenthj-publications-by-citations.pdf>  
**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

94 papers	2,876 citations	29 h-index	50 g-index
97 ext. papers	3,546 ext. citations	5.1 avg, IF	5.3 L-index

#	Paper	IF	Citations
94	Heritability of Schizophrenia and Schizophrenia Spectrum Based on the Nationwide Danish Twin Register. <i>Biological Psychiatry</i> , <b>2018</b> , 83, 492-498	7.9	205
93	Common variants at VRK2 and TCF4 conferring risk of schizophrenia. <i>Human Molecular Genetics</i> , <b>2011</b> , 20, 4076-81	5.6	162
92	Alterations of the brain reward system in antipsychotic naïve schizophrenia patients. <i>Biological Psychiatry</i> , <b>2012</b> , 71, 898-905	7.9	157
91	A gene co-expression network in whole blood of schizophrenia patients is independent of antipsychotic-use and enriched for brain-expressed genes. <i>PLoS ONE</i> , <b>2012</b> , 7, e39498	3.7	101
90	Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. <i>Lancet Psychiatry</i> , <b>2018</b> , 5, 797-807	23.3	100
89	Hippocampal and caudate volume reductions in antipsychotic-naïve first-episode schizophrenia. <i>Journal of Psychiatry and Neuroscience</i> , <b>2010</b> , 35, 95-104	4.5	88
88	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation. <i>World Journal of Biological Psychiatry</i> , <b>2015</b> , 16, 142-70	3.8	84
87	17.3 USING RASCH ANALYSIS TO IDENTIFY NEGATIVE SYMPTOM RESPONSE TRAJECTORIES IN FIRST-EPISEODE SCHIZOPHRENIA. <i>Schizophrenia Bulletin</i> , <b>2019</b> , 45, S116-S116	1.3	78
86	M143. REGIONAL CEREBRAL BLOOD FLOW IN INITIALLY ANTIPSYCHOTIC-NAÏVE PATIENTS WITH SCHIZOPHRENIA OR PSYCHOSIS: EFFECTS OF PARTIAL D2 RECEPTOR AGONISM AND ASSOCIATION WITH SYMPTOM IMPROVEMENT. <i>Schizophrenia Bulletin</i> , <b>2020</b> , 46, S190-S190	1.3	78
85	M148. NORMALIZATION IN REWARD PROCESSING DURING INITIAL TREATMENT MAY PREDICT LONG-TERM CLINICAL OUTCOME IN ANTIPSYCHOTIC NAÏVE SCHIZOPHRENIA PATIENTS. <i>Schizophrenia Bulletin</i> , <b>2020</b> , 46, S191-S192	1.3	78
84	O3.3. REWARD PROCESSING AS A VULNERABILITY INDICATOR FOR PSYCHOSIS: RESULTS FROM A TWIN STUDY. <i>Schizophrenia Bulletin</i> , <b>2018</b> , 44, S80-S80	1.3	78
83	Magnetic resonance imaging and the prediction of outcome in first-episode schizophrenia: a review of current evidence and directions for future research. <i>Schizophrenia Bulletin</i> , <b>2015</b> , 41, 574-83	1.3	68
82	The promise of biological markers for treatment response in first-episode psychosis: a systematic review. <i>Schizophrenia Bulletin</i> , <b>2015</b> , 41, 559-73	1.3	65
81	Progressive striatal and hippocampal volume loss in initially antipsychotic-naïve, first-episode schizophrenia patients treated with quetiapine: relationship to dose and symptoms. <i>International Journal of Neuropsychopharmacology</i> , <b>2011</b> , 14, 69-82	5.8	63
80	Evaluation of a neurodevelopmental model of schizophrenia--early postnatal PCP treatment in attentional set-shifting. <i>Behavioural Brain Research</i> , <b>2008</b> , 190, 160-3	3.4	60
79	Serotonin 2A receptor antagonists for treatment of schizophrenia. <i>Expert Opinion on Investigational Drugs</i> , <b>2011</b> , 20, 1211-23	5.9	56
78	Intragenic deletions affecting two alternative transcripts of the IMMP2L gene in patients with Tourette syndrome. <i>European Journal of Human Genetics</i> , <b>2014</b> , 22, 1283-9	5.3	52

77	Gating of the vertex somatosensory and auditory evoked potential P50 and the correlation to skin conductance orienting response in healthy men. <i>Psychiatry Research</i> , <b>2001</b> , 101, 221-35	9.9	48
76	Striatal Reward Activity and Antipsychotic-Associated Weight Change in Patients With Schizophrenia Undergoing Initial Treatment. <i>JAMA Psychiatry</i> , <b>2016</b> , 73, 121-8	14.5	46
75	Reversal of cognitive deficits by an ampakine (CX516) and sertindole in two animal models of schizophrenia--sub-chronic and early postnatal PCP treatment in attentional set-shifting. <i>Psychopharmacology</i> , <b>2009</b> , 206, 631-40	4.7	46
74	Dopaminergic sensitization: implications for the pathogenesis of schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>1997</b> , 21, 23-46	5.5	45
73	Prepulse inhibition in patients with Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2004</b> , 25, 1045-50	5.6	43
72	Frontal fasciculi and psychotic symptoms in antipsychotic-naïve patients with schizophrenia before and after 6 weeks of selective dopamine D2/3 receptor blockade. <i>Journal of Psychiatry and Neuroscience</i> , <b>2016</b> , 41, 133-41	4.5	40
71	The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics. <i>Schizophrenia Bulletin</i> , <b>2015</b> , 41, 549-58	1.3	38
70	A large European, multicenter, multinational validation study of the Brief Negative Symptom Scale. <i>European Neuropsychopharmacology</i> , <b>2019</b> , 29, 947-959	1.2	36
69	World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia - a short version for primary care. <i>International Journal of Psychiatry in Clinical Practice</i> , <b>2017</b> , 21, 82-90	2.4	35
68	Acute and long-term psychiatric side effects of mefloquine: a follow-up on Danish adverse event reports. <i>Travel Medicine and Infectious Disease</i> , <b>2015</b> , 13, 80-8	8.4	32
67	Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study. <i>Translational Psychiatry</i> , <b>2019</b> , 9, 20	8.6	30
66	Electrical sensitization of the meso-limbic dopaminergic system in rats: a pathogenetic model for schizophrenia. <i>Brain Research</i> , <b>1993</b> , 619, 39-54	3.7	30
65	Intermittent versus continuous neuroleptic treatment in a rat model. <i>European Journal of Pharmacology</i> , <b>1990</b> , 190, 275-86	5.3	29
64	Modeling determinants of medication attitudes and poor adherence in early nonaffective psychosis: implications for intervention. <i>Schizophrenia Bulletin</i> , <b>2015</b> , 41, 584-96	1.3	28
63	Effect of an NCAM mimetic peptide FGL on impairment in spatial learning and memory after neonatal phencyclidine treatment in rats. <i>Behavioural Brain Research</i> , <b>2009</b> , 199, 288-97	3.4	27
62	Striatal D(2/3) Binding Potential Values in Drug-Naïve First-Episode Schizophrenia Patients Correlate With Treatment Outcome. <i>Schizophrenia Bulletin</i> , <b>2015</b> , 41, 1143-52	1.3	26
61	Intermittent neuroleptic treatment induces long-lasting abnormal mouthing in the rat. <i>European Journal of Pharmacology</i> , <b>1989</b> , 164, 393-6	5.3	26
60	Objective and subjective sleep quality: Melatonin versus placebo add-on treatment in patients with schizophrenia or bipolar disorder withdrawing from long-term benzodiazepine use. <i>Psychiatry Research</i> , <b>2016</b> , 240, 163-169	9.9	26

59	Two subgroups of antipsychotic-naïve, first-episode schizophrenia patients identified with a Gaussian mixture model on cognition and electrophysiology. <i>Translational Psychiatry</i> , <b>2017</b> , 7, e1087	8.6	25
58	Patterns of white matter microstructure in individuals at ultra-high-risk for psychosis: associations to level of functioning and clinical symptoms. <i>Psychological Medicine</i> , <b>2017</b> , 47, 2689-2707	6.9	25
57	Auditory processing in autism spectrum disorder: Mismatch negativity deficits. <i>Autism Research</i> , <b>2017</b> , 10, 1857-1865	5.1	25
56	No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , <b>2017</b> , 136, 52-62	6.5	24
55	Structural brain correlates of sensorimotor gating in antipsychotic-naïve men with first-episode schizophrenia. <i>Journal of Psychiatry and Neuroscience</i> , <b>2013</b> , 38, 34-42	4.5	24
54	Normal P50 Gating in Children with Autism, Yet Attenuated P50 Amplitude in the Asperger Subcategory. <i>Autism Research</i> , <b>2015</b> , 8, 371-8	5.1	22
53	Assessment of auditory sensory processing in a neurodevelopmental animal model of schizophrenia--gating of auditory-evoked potentials and prepulse inhibition. <i>Behavioural Brain Research</i> , <b>2010</b> , 213, 142-7	3.4	21
52	Cerebral glutamate and GABA levels in high-risk of psychosis states: A focused review and meta-analysis of H-MRS studies. <i>Schizophrenia Research</i> , <b>2020</b> , 215, 38-48	3.6	21
51	Heritability of cerebral glutamate levels and their association with schizophrenia spectrum disorders: a [H]-spectroscopy twin study. <i>Neuropsychopharmacology</i> , <b>2019</b> , 44, 581-589	8.7	21
50	Mismatch negativity and P3a amplitude in young adolescents with first-episode psychosis: a comparison with ADHD. <i>Psychological Medicine</i> , <b>2017</b> , 47, 377-388	6.9	19
49	Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits. <i>BMC Medicine</i> , <b>2012</b> , 10, 92	11.4	19
48	Information processing and attentional dysfunctions as vulnerability indicators in schizophrenia spectrum disorders. <i>World Journal of Biological Psychiatry</i> , <b>2000</b> , 1, 5-15	3.8	19
47	Low frontal serotonin 2A receptor binding is a state marker for schizophrenia?. <i>European Neuropsychopharmacology</i> , <b>2016</b> , 26, 1248-50	1.2	19
46	Persistent vacuous chewing in rats following neuroleptic treatment: relationship to dopaminergic and cholinergic function. <i>Psychopharmacology</i> , <b>1993</b> , 113, 157-66	4.7	18
45	White matter maturation during 12 months in individuals at ultra-high-risk for psychosis. <i>Acta Psychiatrica Scandinavica</i> , <b>2018</b> , 137, 65-78	6.5	18
44	Multiple measures of HPA axis function in ultra high risk and first-episode schizophrenia patients. <i>Psychoneuroendocrinology</i> , <b>2018</b> , 92, 72-80	5	17
43	Systemic oxidative DNA and RNA damage are not increased during early phases of psychosis: A case control study. <i>Psychiatry Research</i> , <b>2016</b> , 241, 201-6	9.9	17
42	Glutamate Levels and Resting Cerebral Blood Flow in Anterior Cingulate Cortex Are Associated at Rest and Immediately Following Infusion of S-Ketamine in Healthy Volunteers. <i>Frontiers in Psychiatry</i> , <b>2018</b> , 9, 22	5	15

41	Neocortical serotonin <sub>2A</sub> receptor binding predicts quetiapine associated weight gain in antipsychotic-naïve first-episode schizophrenia patients. <i>International Journal of Neuropsychopharmacology</i> , <b>2014</b> , 17, 1729-36	5.8	15
40	Is an Early Age at Illness Onset in Schizophrenia Associated With Increased Genetic Susceptibility? Analysis of Data From the Nationwide Danish Twin Register. <i>EBioMedicine</i> , <b>2017</b> , 18, 320-326	8.8	14
39	Circadian rest-activity rhythms during benzodiazepine tapering covered by melatonin versus placebo add-on: data derived from a randomized clinical trial. <i>BMC Psychiatry</i> , <b>2016</b> , 16, 348	4.2	14
38	A mixed modality paradigm for recording somatosensory and auditory P50 gating. <i>Psychiatry Research</i> , <b>2001</b> , 105, 79-86	9.9	14
37	Association of Adverse Outcomes With Emotion Processing and Its Neural Substrate in Individuals at Clinical High Risk for Psychosis. <i>JAMA Psychiatry</i> , <b>2020</b> , 77, 190-200	14.5	14
36	Effects of Blocking D <sub>2</sub> /D <sub>3</sub> Receptors on Mismatch Negativity and P3a Amplitude of Initially Antipsychotic Naïve, First Episode Schizophrenia Patients. <i>International Journal of Neuropsychopharmacology</i> , <b>2015</b> , 19, pyv109	5.8	14
35	Alterations of Intrinsic Connectivity Networks in Antipsychotic-Naïve First-Episode Schizophrenia. <i>Schizophrenia Bulletin</i> , <b>2018</b> , 44, 1332-1340	1.3	13
34	Decreased gene expression of neuropeptide Y and its receptors in hippocampal regions during ethanol withdrawal in rats. <i>Neuroscience Letters</i> , <b>2007</b> , 424, 160-4	3.3	13
33	Negative Symptoms and Reward Disturbances in Schizophrenia Before and After Antipsychotic Monotherapy. <i>Clinical EEG and Neuroscience</i> , <b>2018</b> , 49, 36-45	2.3	13
32	Remission from antipsychotic treatment in first episode psychosis related to longitudinal changes in brain glutamate. <i>NPJ Schizophrenia</i> , <b>2019</b> , 5, 12	5.5	12
31	The relation between dopamine D receptor blockade and the brain reward system: a longitudinal study of first-episode schizophrenia patients. <i>Psychological Medicine</i> , <b>2020</b> , 50, 220-228	6.9	12
30	Development of vacuous chewing movements in rats: role of housing environment. <i>Life Sciences</i> , <b>1991</b> , 48, 2137-40	6.8	11
29	Associations Between Cognitive Function and Levels of Glutamatergic Metabolites and Gamma-Aminobutyric Acid in Antipsychotic-Naïve Patients With Schizophrenia or Psychosis. <i>Biological Psychiatry</i> , <b>2021</b> , 89, 278-287	7.9	11
28	Selective attention and mismatch negativity in antipsychotic-naïve, first-episode schizophrenia patients before and after 6 months of antipsychotic monotherapy. <i>Psychological Medicine</i> , <b>2017</b> , 47, 2155-2165 <sup>10</sup>	6.9	10
27	Validation of the Danish version of the brief negative symptom scale. <i>Nordic Journal of Psychiatry</i> , <b>2019</b> , 73, 425-432	2.3	10
26	Proprioceptive evoked potentials in man: cerebral responses to changing weight loads on the hand. <i>Neuroscience Letters</i> , <b>2000</b> , 288, 111-4	3.3	10
25	Differential effects of age at illness onset on verbal memory functions in antipsychotic-naïve schizophrenia patients aged 12-43 years. <i>Psychological Medicine</i> , <b>2021</b> , 51, 1570-1580	6.9	9
24	Delay Aversion and Executive Functioning in Adults With Attention-Deficit/Hyperactivity Disorder: Before and After Stimulant Treatment. <i>International Journal of Neuropsychopharmacology</i> , <b>2018</b> , 21, 997-1006	5.8	8

23	Startle habituation, sensory, and sensorimotor gating in trauma-affected refugees with posttraumatic stress disorder. <i>Psychological Medicine</i> , <b>2019</b> , 49, 581-589	6.9	8
22	Glucocorticoids and the risk of schizophrenia spectrum disorder in childhood and adolescence - A Danish nationwide study. <i>Schizophrenia Research</i> , <b>2018</b> , 199, 116-122	3.6	7
21	Overlapping and disease specific trait, response, and reflection impulsivity in adolescents with first-episode schizophrenia spectrum disorders or attention-deficit/hyperactivity disorder. <i>Psychological Medicine</i> , <b>2018</b> , 48, 604-616	6.9	7
20	Cerebral Glutamate and Gamma-Aminobutyric Acid Levels in Individuals at Ultra-high Risk for Psychosis and the Association With Clinical Symptoms and Cognition. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , <b>2020</b> , 5, 569-579	3.4	7
19	Effect of a dopamine D-1 agonist in rats treated chronically with zuclopenthixol. <i>Life Sciences</i> , <b>1990</b> , 47, 1339-46	6.8	6
18	Associations of neural processing of reward with posttraumatic stress disorder and secondary psychotic symptoms in trauma-affected refugees. <i>Høje Utbildning</i> , <b>2020</b> , 11, 1730091	5	5
17	Electrical kindling of rats treated discontinuously or continuously with haloperidol. <i>European Journal of Pharmacology</i> , <b>1993</b> , 236, 401-9	5.3	5
16	Visual attention in adults with attention-deficit/hyperactivity disorder before and after stimulant treatment. <i>Psychological Medicine</i> , <b>2019</b> , 49, 2617-2625	6.9	5
15	Extrastriatal dopamine D receptors and cortical grey matter volumes in antipsychotic-naïve schizophrenia patients before and after initial antipsychotic treatment. <i>World Journal of Biological Psychiatry</i> , <b>2017</b> , 18, 539-549	3.8	4
14	Norquetiapine and depressive symptoms in initially antipsychotic-naïve first-episode schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , <b>2013</b> , 33, 266-9	1.7	4
13	Effects of chronic discontinuous and continuous treatment of rats with a dopamine D1 receptor antagonist (NNC-756). <i>European Journal of Pharmacology</i> , <b>1993</b> , 242, 283-91	5.3	4
12	Testing a decades-old assumption: Are individuals with lower sensory gating indeed more easily distracted?. <i>Psychiatry Research</i> , <b>2017</b> , 255, 387-393	9.9	3
11	Baseline measures of cerebral glutamate and GABA levels in individuals at ultrahigh risk for psychosis: Implications for clinical outcome after 12 months. <i>European Psychiatry</i> , <b>2020</b> , 63, e83	6	3
10	Interview and questionnaire assessment of cognitive impairment in subjects at ultra-high risk for psychosis: Associations with cognitive test performance, psychosocial functioning, and positive symptoms. <i>Psychiatry Research</i> , <b>2020</b> , 294, 113498	9.9	3
9	Generalized neurocognitive impairment in individuals at ultra-high risk for psychosis: The possible key role of slowed processing speed. <i>Brain and Behavior</i> , <b>2021</b> , 11, e01962	3.4	3
8	Dopaminergic Activity in Antipsychotic-Naïve Patients Assessed With Positron Emission Tomography Before and After Partial Dopamine D Receptor Agonist Treatment: Association With Psychotic Symptoms and Treatment Response. <i>Biological Psychiatry</i> , <b>2021</b> ,	7.9	3
7	Associations between facial affect recognition and neurocognition in subjects at ultra-high risk for psychosis: A case-control study. <i>Psychiatry Research</i> , <b>2020</b> , 290, 112969	9.9	2
6	Baseline levels of C-reactive protein and proinflammatory cytokines are not associated with early response to amisulpride in patients with First Episode Psychosis: the OPTiMiSE cohort study. <i>Schizophrenia Bulletin Open</i> ,	2.2	2

5	Auditory sensory gating in young adolescents with early-onset psychosis: a comparison with attention deficit/hyperactivity disorder. <i>Neuropsychopharmacology</i> , <b>2020</b> , 45, 649-655	8.7	1
4	The relative and interactive impact of multiple risk factors in schizophrenia spectrum disorders: a combined register-based and clinical twin study. <i>Psychological Medicine</i> , 1-11	6.9	1
3	Effects of methylphenidate on sensory and sensorimotor gating of initially psychostimulant-naïve adult ADHD patients. <i>European Neuropsychopharmacology</i> , <b>2021</b> , 46, 83-92	1.2	0
2	No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia. Authors' response. <i>Acta Psychiatrica Scandinavica</i> , <b>2017</b> , 136, 526-527	6.5	
1	Effects of methylphenidate on subjective sleep parameters in adults with ADHD: a prospective, non-randomized, non-blinded 6-week trial. <i>Nordic Journal of Psychiatry</i> , 1-6	2.3	